share_log

Keybanc Maintains Overweight on Codex DNA, Lowers Price Target to $5

Benzinga Real-time News ·  Nov 9, 2022 04:51

Keybanc analyst Paul Knight maintains Codex DNA (NASDAQ:DNAY) with a Overweight and lowers the price target from $8 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment